Based in Los Angeles, Enochian BioSciences Inc. is an immunotherapy company with a clear mission: develop definitive cures and provide effective prevention for infectious diseases and cancer.

After the acquisition of Enochian Biopharma early 2018, Enochian Biosciences Inc. (former DanDrit Biotech USA Inc.) is poised to change the course of immunotherapy treatments through expert insights and dedicated efforts.

Our objectives:

  • HIV preventative vaccine and cures
  • Cellular immune-oncology products for the prevention of relapse of metastatic colon cancer after resection and chemotherapy
  • Allogeneic Dendritic Cell for treatment of cancer

Management Team

Our core management team combines the relevant HIV/AIDS and oncology development experience: Pharmaceutical industry, biotech and academia.

We opt for outsourcing manufacturing and regulatory (based on past experience of other biotech companies developing advanced therapies).


  • Dr. Eric Leire, MD, MBA

    Chief Executive Officer

    Dr. Eric Leire, MD, MBA

    Brings to the Company his experience in pharmaceutical industry (Pfizer, Schering Plough, Pharmacia), biotechnology (CEO of private and public biotech companies), academia (Research Associate at the Harvard AIDS Institute) and Private Equity (partner at Biofund Venture Capital).   He is the inventor of several patents. He also serves on the board of Novicol,  (Canada).  He holds an MD from Grenoble University and an MBA from HEC and Kellogg, Northwestern University.

  • Mr. Robert Wolfe

    Chief Financial Officer

    Mr. Robert Wolfe

    Previously served as the Chief Financial Officer of Enochian in 2014. Mr Wolfe also serves as Chairman and CEO of IProcess Manager Inc. from April 2010, and Director of Iso-Ware A/S from February 2006. Mr. Wolfe has served as President, CEO and director of Crossfield, Inc., Crossfield Investments, LLC, Drumbeg Ltd, Baldwin Construction Inc., and Ludlow Leasing, Inc. from May 1989 to the present. The Board believes that Mr. Wolfe’s experience with U.S. public companies and Danish entities qualifies Mr. Wolfe to serve as CFO of the Company.

  • Dr. Wenshi Wang

    SVP Operations

    Dr. Wenshi Wang

    Dr. Wang has been actively overseeing, working and completing Investigation New Drug (IND) filing with FDA on stem cell and T cell therapy demonstrating her leadership in drug discovery and development. Dr. Wang completed her clinical medicine and her Immunology PhD training in China and at Heidelberg University in Germany. In the United States, Dr. Wang advanced her career in translational immune-oncology at the University of Southern California and Moffitt Cancer Center in Florida with achievements in patent issuance and publications in the industry’s top peer-reviewed journals.

  • Dr. Serhat Gümrükcü


    Dr. Serhat Gümrükcü

    Has over a decade of research and practice in the field of personalized medicine, focusing on regenerative treatment modalities using stem cell technologies, biological treatments, cancer immunotherapy, and nanoparticle delivery systems.

    Dr. Gumrukcu’s pioneering practice has led to multiple breakthrough achievements in the field of regenerative medicine for patients suffering from traumatic or chronic degenerative diseases including cerebral palsy, stroke, brain and spinal injuries causing paralysis, degenerative eye (optic nerve or retina) diseases resulting with blindness, as well as autoimmune and chronic degenerative diseases like MS, Myasthenia Gravis, Alzheimer’s disease, Parkinson’s disease and many others alike.

    He believes in personalized treatment for cancer and continues his research studies in the field of cancer immunotherapy. His work directed towards developing a sterilizing HIV cure brought AGTHERA to life, which incorporates the principles of gene therapy with a novel method of bone marrow transplant. Along with AGTHERA, his nanoparticle-based protective HIV vaccine HIVMUNE, the off-the-shelf Adenovirus based therapeutic colorectal cancer vaccine, and his universal dendritic cell vaccine for solid tumors are also under development at Enochian Biosciences. After studying Medicine in Turkey, he has continued his education in Comparative Religion and Psychology while he resumed his research in Personalized and Regenerative Medicine that extended throughout Europe, Middle East and Asia. He speaks seven languages.

  • Mr. Tung Nguyen

    Senior Molecular Biologist

    Mr. Tung Nguyen

    Devoting more than a quarter of a century on research with focus on signal transduction and molecular basic of cancer and infection, Tung is eager to transform his passion for Science into cures for diseases, to fulfill his life-long wish on helping people and saving lives.

    He conducted research at the Molecular Oncology Department at John Wayne Cancer Institute, the Molecular Host Defense Laboratory at UCLA and the Molecular Immunology at Beckman Research Institute at City of Hope Medical Center. And “this is exactly where I want to be today …”, he stated upon joining Enochian Biosciences team.

Transformative & Compassionate Information

Board of Directors

The board of directors includes:

  • Mr. Rene Sindlev


    Mr. Rene Sindlev

    Is a recognized Danish entrepreneur with a solid track record as creative and innovative Business Developer. He is the co-founder of Enochian Biosciences.  He is also currently the founder and owner of Dr.Smood, a chain of healthy fast casual food & beverage stores. Mr. Sindlev was also co-founder and President of Pandora Jewelry.  He is the owner of several companies such as RS Group ApS, RS Trylleskoven 1 ApS and RS Arving ApS.

  • Dr. Mark Dybul

    Vice Chairman

    Dr. Mark Dybul

    The Honorable Mark Dybul, MD, is a Professor in the Department of Medicine at Georgetown University Medical Center, and the Faculty Co-Director of the Center for Global Health and Quality.  Mark has worked on HIV and public health for nearly 30 years as a clinician, scientist, teacher, and administrator, most recently as the Executive Director of the Global Fund to Fight AIDS, Tuberculosis and Malaria. After graduating from Georgetown Medical School in Washington D.C., Mark joined the National Institute of Allergy and Infectious Diseases, as a research fellow under director Dr. Anthony Fauci, where he conducted basic and clinical studies on HIV virology, immunology and treatment optimization, including the first randomized, controlled trial with combination antiretroviral therapy in Africa. Mark was one of the founding architects in the formation of the U.S. President’s Emergency Plan for AIDS Relief, better known as PEPFAR. After serving as Chief Medical officer, Assistant, Deputy and Acting Director, he was appointed as its leader in 2006, becoming U.S. Global AIDS Coordinator, with the rank of Ambassador at the level of an Assistant Secretary of State. He served until early 2009.  Mark has written extensively in scientific and policy literature, and has received several Honorary Degrees and awards, including a Doctor of Science, Honoris Causa, from Georgetown University.

  • Luc Debruyne

    Independent director

    Luc Debruyne

    Bio Coming Soon

  • Ms. Evelyn D’An

    Independent director

    Ms. Evelyn D’An

    Evelyn D’An is a Senior Executive, Corporate Director, Former Big 4 Audit Partner and Hispanic financial leader with broad based global financial experience in publicly traded companies and professional services with a Big 4 accounting firm. She has held numerous CFO positions during her career. Ms. D’An currently runs a consulting business where she primarily provides outsourced CFO services – working closely with founding CEOs and helping implement strong processes both on the front end of the business cycle as well as back office operations.  She has helped companies implement incentive compensation plans aligned with overall company strategies. Her years of experience have enabled her to become an excellent sounding board for CEOs as they build strategies for future growth and sustainability.

    Ms. D’An began her career with Ernst & Young and was named the first Hispanic female partner in the Southeast region. She was with Ernst & Young for 18 years, of which 8 years she was a partner in the audit practice and represented multiple public companies with wide ranging financial and audit challenges, including numerous IPOs.

    Ms. D’An currently serves on the Board and Audit Committee of Summer Infant, a $200M NASDAQ registered global leader in premium infant and juvenile products. She was a Director of Hot Topic, the $800M NASDAQ registered teen specialty retailer, until its sale in 2013. She chaired the Audit Committee and the Nominating Committee, during which there was a successful transition of several board members, the Chairman of the Board, and succession of the Chief Executive Officer. In addition, she served as a member of the Board of Directors and Chair of the Audit Committee for Alico, Inc., the $200M NASDAQ registered land management company specializing in agricultural and property development operations.

  • James Sapirstein

    Independent director

    James Sapirstein

    James Sapirstein, R.Ph. joins the Board of Directors of Enochian having served over thirty years in the pharmaceutical industry.  He has been part of almost two dozen product launches and specifically either led or been a key member of several HIV product launches into a new class of therapeutics at that time. He is currently the CEO of ContraVir Pharmaceuticals, Inc., which is a company specializing in the Hepatitis B space.  After beginning his career in 1984 with Eli Lilly, he accepted a position at Hoffmann-LaRoche in 1987, where he served for almost a decade as part of its commercial teams in the US and abroad. He held a number of positions at Hoffmann-LaRoche, before moving to Bristol Myers Squibb in 1996 the Director of International Marketing in the Infectious Disease group. While at BMS, he worked on several important HIV/AIDS projects including Secure the Future.

    Mr. Sapirstein started his career in smaller biotech companies when he later joined Gilead Sciences, Inc. (GILD) in order to lead the Global Marketing team in its launch of Viread (tenofovir) In 2002, he accepted the position of Executive Vice President Metabolic and Endocrinology for Serono Laboratories before becoming the founding CEO of Tobira Therapeutics in 2006. In 2012, after several years in the infectious diseases space, Mr. Sapirstein became the CEO of Alliqua Therapeutics at Alliqua, Inc., prior to joining Contravir.

    Mr. Sapirstein holds board positions on RespireRx Pharmaceuticals (RSPI) and Leading Biosciences. He is also the Chairman of BioNJ and a Board Director for BIO, where he sits on both the Health Section Governing and Emerging Companies Section Governing Boards.

  • Mr. Carl Sandler


    Mr. Carl Sandler

    Mr. Sandler is a serial tech and healthcare CEO who has built numerous consumer-facing technology and healthcare brands. Mr. Sandler is a widely respected thought leader, journalist and speaker on issues related to public health, HIV / AIDS, sex and sexuality. He has spoken extensively at AIDS / HIV conferences worldwide about innovative uses of technology in public health.
    Former CEO of Enochian BioPharma, Inc. successfully acquired by DanDrit. Co-manager and Co-founder of Weird Science, LLC.
    Educated in Economics from Stanford University.
  • Henrik Grønfeldt-Sørensen


    Henrik Grønfeldt-Sørensen

    Has + 10 years experience from different CEO & management positions; Danske Bank in Denmark, the Danish Bank Nykredit in France. RS Group of Companies, a family office in Denmark with global investments within real estate, charter business, food & beverage, private hospitals and biosciences.

    Partner and board member in Dr Smood ApS, Enochian BioSciences Inc & RS Newton ApS.

    Last education: eMBA from The International University of Monaco.

  • Dr. Eric Leire, MD, MBA

    CEO & Board Observer

    Dr. Eric Leire, MD, MBA

    Brings to the Company his experience in pharmaceutical industry (Pfizer, Schering Plough, Pharmacia), biotechnology (CEO of private and public biotech companies), academia (Research Associate at the Harvard AIDS Institute) and Private Equity (partner at Biofund Venture Capital).   He is the inventor of several patents. He also serves on the board of Novicol,  (Canada).  He holds an MD from Grenoble University and an MBA from HEC and Kellogg, Northwestern University.

Committed to Our Vision of Curing Patients with Infectious Diseases and Cancers

Scientific Advisory Board

The Scientific Advisory Board (SAB) with HIV/AIDS expertise includes:

  • Dr. Mark Dybul


    Dr. Mark Dybul

    Ambassador Mark R. Dybul has served as Deputy Chief Medical Officer of PEPFAR since 2004. Ambassador Dybul co-directs the Global Health Law Program at Georgetown University Law Center’s O’Neill Institute for National and Global Health Law, where he is also a Distinguished Visiting Scholar. He is the inaugural Global Health Fellow of the George W. Bush Institute and serves as the Managing Director of the Office of the United Nation Special Envoy for Malaria. He served as the United States Global AIDS Coordinator from 2006 to the end of the George W. Bush administration in January 2009.

  • Dr. Steven G. Deeks


    Dr. Steven G. Deeks

    Is a Professor of Medicine in Residence at the University of California, San Francisco (UCSF) and a faculty member in the Division of HIV, Infectious Diseases and Global Medicine at Zuckerberg San Francisco General Hospital. Dr. Deeks has been engaged in HIV research and clinical care since 1993. He is a recognized expert on HIV-associated immune dysfunction and its impact on HIV persistence (the “reservoir”) and health during antiretroviral therapy.

  • Dr. HP Kiem


    Dr. HP Kiem

    Dr. Kiem’s research has focused on stem cell and transplantation biology, cell and gene therapy and the development and use of novel gene editing technologies. The overall goal has been the development of improved treatment approaches for patients with genetic and infectious diseases and cancer. Dr. Kiem has extensive experience training students and postdoctoral fellows and has mentored more than 50 trainees in his lab over the past 20 years. Many of his trainees now hold tenured faculty positions in the US and in Germany. Dr. Kiem is the Sponsor of 4 clinical gene therapy studies (HIV, glioblastoma, and Fanconi anemia) and he is the PI or Co-PI of many R01 or P01 grants including a Martin Delaney Consortium grant to study HIV cure strategies (defeatHIV). Dr. Kiem has also served on the NIH Recombinant DNA Advisory Committee (RAC) for 5 years and the last year as Chair. He is currently the Chair of the Stem Cell Committees for both the American Society for Gene and Cell Therapy (ASGCT) and the American Society of Hematology.

  • Dr. W. David Hardy


    Dr. W. David Hardy

    Dr. W. David Hardy currently serves as Senior Director of Evidence-based Practices, ACTG clinical research site (CRS) leader, MACS co-investigator and HIV/primary care provider at Whitman-Walker Health in Washington, D.C. He holds an Adjunct Professor of Medicine appointment at Johns Hopkins University School of Medicine in Baltimore. He previously served as Director, Division of Infectious Diseases at Cedars-Sinai Medical Center and Professor of Medicine at the David Geffen School of Medicine at UCLA. Just prior to joining Whitman-Walker, Dr. Hardy was Chief Medical Officer for Calimmune, a biotech company investigating gene-modified CD4+ T cells and hematopoietic stem cells as a potential cure for HIV infection.

    Dr. Hardy currently also serves on the Board of Directors of the American Academy of HIV Medicine and chair of the Education Committee. He served as editor-in-chief of the American Academy of HIV Medicine (AAHIVM) comprehensive textbook, Fundamentals of HIV Medicine for the HIV Specialist published in 2012 and 2016. Dr. Hardy also served on the Board of Directors of the HIV Medicine Association (HIVMA) as an infectious diseases representative from 2011-2014.